Tests TQ05105 tablets in adults with intermediate or high-risk myelofibrosis
Tests TQ05105 tablets in adults with myelofibrosis who did not respond to earlier JAK inhibitors.
Key facts
- Who runs it
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Where
- Cangzhou, Changchun, Changzhi, Chengde, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Nanjin, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Ürümqi, Wuhan, Xi’an, Xingtai, Zhengzhou, and Zhuzhou, ChinaSee the 24 sites
- Trial code
- Registry title
- A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 51 people, planned
- Started
- 18 Jun 2026
- Expected to end
- Jun 2029
- Type of study
- Interventional
- Treatments tested
- TQ05105 Tablets (Rovadicitinib Tablets)
- Record updated
- 15 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with intermediate or high-risk myelofibrosis. One group has normal, mild or moderate kidney function. The other group had a JAK inhibitor that stopped working, stopped helping, or caused side effects.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Primary myelofibrosis, or myelofibrosis after polycythemia vera or essential thrombocythemia. Intermediate or high risk by DIPSS. Blasts in blood and bone marrow 10% or lower. Enlarged spleen, except in the kidney function group.
- Earlier treatment
- The second group must have had a JAK inhibitor that did not work, stopped working, or was not tolerated. No more than 1 prior JAK inhibitor in that group. No growth factors, colony-stimulating factors, thrombopoietin or platelet transfusion in the 2 weeks before the first dose.
- Biomarker or test result
- JAK2 mutation status does not matter.
Main reasons for not taking part
- Earlier donor stem cell transplant, or planned stem cell transplant
- Removal of the spleen, or radiation to the spleen, within 6 months
- Active hepatitis B or hepatitis C infection
- Kidney failure needing dialysis
- History of organ transplant or immune deficiency
The registry criteria, word for word
Show all 36 criteriaShow less
Who can take part
- Voluntary and signed informed consent, good compliance
- Age ≥18 years (at time of signing informed consent); Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2; life expectancy ≥24 weeks
- Diagnosis of primary myelofibrosis (PMF) per World Health Organization (WHO) 2016, or post-polycythemia vera myelofibrosis (post-PV-MF) or post-essential thrombocythemia myelofibrosis (post-ET-MF) per International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) criteria; Janus kinase 2 (JAK2) mutation status not restricted
- Intermediate or high risk per Dynamic International Prognostic Scoring System (DIPSS)
- Cohort 1: Renal function classified as normal, mild impairment, or moderate impairment. Cohort 2: Prior Janus kinase (JAK) inhibitor therapy with refractory, relapsed, or intolerant
- Spleen enlargement (except Cohort 1)
- Peripheral blood and bone marrow blasts ≤10%
- No growth factors, colony-stimulating factors, thrombopoietin, or platelet transfusion within 2 weeks before first dose; and routine blood parameters meet requirements within 7 days before first dose
- Adequate major organ function within 7 days before first dose per protocol (renal function not restricted for Cohort 1)
- Agreement to use effective contraception during the study and for 6 months after; negative pregnancy test for females of childbearing potential; non-lactating
Who cannot take part
- Prior allogeneic stem cell transplantation, or autologous stem cell transplantation within 3 months before first dose, or planned stem cell transplantation
- Prior treatment with 2 or more Janus kinase (JAK) inhibitors (except Cohort 1)
- Prior splenectomy or splenic radiotherapy within 6 months before first dose
- Factors affecting oral drug absorption
- Non-hematologic toxicity from prior therapy not recovered to ≤ grade 1 (excluding hypertension and alopecia)
- Major surgery or significant traumatic injury within 4 weeks before first dose
- Arterial/venous thrombosis event within 6 months before first dose
- Newly diagnosed pulmonary interstitial fibrosis or drug-related interstitial lung disease within 3 months before first dose
- Use of protocol-prohibited myelofibrosis (MF) medications, immunomodulators, or immunosuppressants within specified time before first dose
- Use of Chinese patent medicines with anti-tumor indications approved by National Medical Products Administration (NMPA) within 2 weeks before first dose
- Live attenuated vaccine within 4 weeks before first dose or planned during the study
- Participation in another interventional clinical trial with investigational drug within 4 weeks before first dose
- Other malignancies within 3 years before first dose or currently present (exceptions per protocol)
- Congenital bleeding or coagulation disorders
- History of substance abuse or mental disorder
- Active or uncontrolled severe infection
- Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
- Uncontrolled hypertension despite standard therapy
- Renal failure requiring hemodialysis or peritoneal dialysis
- History of immunodeficiency or organ transplantation
- Epilepsy requiring treatment
- Known hypersensitivity to study drug or excipients
- Diagnosis of active autoimmune disease within 2 years before first dose
- Any condition that, in the investigator's judgment, seriously endangers subject safety or interferes with study completion
- Grade ≥2 myocardial ischemia or infarction, arrhythmia, QT prolongation, or grade ≥2 congestive heart failure
- Uncontrolled pleural effusion, pericardial effusion, or ascites
Where in China
- Cangzhou People's Hospital rovinceCangzhou, ChinaContact: Hongmei Ma, MasterTaking people
- The First Hospital of Jilin UniversityChangchun, ChinaContact: Sujun Gao, DoctorTaking people
- Heping Hospital Affiliated to Changzhi Medical CollegeChangzhi, ChinaContact: Xuliang Shen, DoctorTaking people
- Affiliated Hospital of Chengde Medical CollegeChengde, ChinaContact: Zhihua Zhang, MasterTaking people
- Sichuan Provincial People's HospitalChengdu, ChinaContact: Xiaobing Huang, DoctorTaking people
- Fujian Medical University Union HospitalFuzhou, ChinaContact: Yong Wu, DoctorTaking people
- Guangzhou First Municipal People's HospitalGuangzhou, ChinaContact: Shunqing Wang, DoctorTaking people
- The First Affiliated Hospital Zhejiang University School of MedicineHangzhou, ChinaContact: Hongyan Tong, DoctorTaking people
- The First Affiliated Hospital of University of Science and Technology of ChinaHefei, ChinaContact: Xiaoyu Zhu, DoctorTaking people
- Nanjing Drum Tower HospitalNanjin, ChinaContact: Bing Chen, DoctorTaking people
- Jiangsu Provincial Hospital of Traditional Chinese MedicineNanjing, ChinaContact: Xuejun Zhu, DoctorTaking people
- The First Affiliated Hospital of Guangxi Medical UniversityNanning, ChinaContact: Zhenfang Liu, DoctorTaking people
- Shanghai Sixth People's HospitalShanghai, ChinaContact: Chunkang Chang, DoctorTaking people
- Shengjing Hospital affiliated to China Medical UniversityShenyang, ChinaContact: Huihan Wang, DoctorTaking people
- The Second Hospital of Hebei Medical UniversityShijiazhuang, ChinaContact: Xuejun Zhang, DoctorTaking people
- Chinese Academy of Medical Sciences Hematology HospitalTianjin, ChinaContact: Bo Jiang, DoctorTaking people
- The First Affiliated Hospital of Xinjiang Medical UniversityÜrümqi, ChinaContact: Jianping Hao, MasterTaking people
- Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & TechnologyWuhan, ChinaContact: Zhenya Hong, PostdoctoralTaking people
- Union Hospital Tongji College Huazhong University of Science and TechnologyWuhan, ChinaContact: Min Zhang, DoctorTaking people
- The First Affiliated Hospital of Air Force Medical UniversityXi’an, ChinaContact: Guangxun Gao, DoctorTaking people
- The First Affiliated Hospital of Xi'an Jiaotong UniversityXi’an, ChinaContact: Pengcheng He, DoctorTaking people
- Xingtai People's HospitalXingtai, ChinaContact: Zongjiu Jiao, MasterTaking people
- Henan Cancer HospitalZhengzhou, ChinaContact: Hu Zhou, DoctorTaking people
- Zhuzhou Central HospitalZhuzhou, ChinaContact: Chanjuan Shen, MasterTaking people
About the trial
What the trial wants to find out
This is an open-label, single-arm, multi-center phase II study consisting of two cohorts. Cohort 1 evaluates the pharmacokinetics (PK) of TQ05105 in myelofibrosis participants with normal, mild, or moderate renal impairment to guide dosing. Cohort 2 evaluates the efficacy and safety of TQ05105 in participants with intermediate/high-risk myelofibrosis who are refractory, relapsed, or intolerant to prior Janus kinase (JAK) inhibitor therapy.
The group in the trial
- TQ05105 TabletsTreatment being tested
TQ05105 Tablets, 28 days as a treatment cycle.
Treatment: TQ05105 Tablets (Rovadicitinib Tablets)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase II, Single-arm, Open-label, Multicenter Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis
- Plain-language title
- Tests TQ05105 tablets in adults with intermediate or high-risk myelofibrosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 15 July 2026